Larimar Therapeutics, Inc. (LRMR)
| Market Cap | 387.94M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -64.77M |
| Shares Out | 63.81M |
| EPS (ttm) | -1.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 666,422 |
| Open | 6.40 |
| Previous Close | 6.38 |
| Day's Range | 5.94 - 6.60 |
| 52-Week Range | 3.09 - 13.68 |
| Beta | 0.71 |
| Analysts | Strong Buy |
| Price Target | 19.63 (+222.86%) |
| Earnings Date | Oct 30, 2024 |
About LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for LRMR stock is "Strong Buy." The 12-month stock price forecast is $19.63, which is an increase of 222.86% from the latest price.
News
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
BALA CYNWYD, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- October 30, 2024 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for ...
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock
Oppenheimer has initiated coverage on Larimar Therapeutics LRMR, a clinical-stage biotechnology company focused on developing treatments for rare diseases.
Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential
Larimar Therapeutics' CTI-1601, a potential first-in-class treatment for Friedreich's ataxia, shows promise in modifying disease progression and restoring mitochondrial function. The company has a sol...
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea...
Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed
Partial clinical hold from FDA, for use of nomlabofusp for the treatment of patients with Friedreich's Ataxia completely lifted; higher dosing of 50 mg of treatment now possible. It is expected that t...
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia
BALA CYNWYD, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disease...
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia
BALA CYNWYD, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disease...
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
BALA CYNWYD, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea...
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
BALA CYNWYD, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dis...
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia
BALA CYNWYD, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dis...
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
BALA CYNWYD, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dis...
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
BALA CYNWYD, Pa., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
BALA CYNWYD, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar Therapeutics Announces Proposed Underwritten Public Offering
BALA CYNWYD, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia
BALA CYNWYD, Pa., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
BALA CYNWYD, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference
BALA CYNWYD, Pa., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors
BALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference
BALA CYNWYD, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
BALA CYNWYD, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar: Friedreich's Ataxia Drug With Significant Potential
Clearance given by FDA to initiate higher 50 mg dosing of CTI-1601 for patients with Friedreich's Ataxia for phase 2 study; results from this cohort expected 1st half of 2024. Clearance given to initi...
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial
BALA CYNWYD, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
BALA CYNWYD, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar Therapeutics Set to Join Russell 3000® Index
BALA CYNWYD, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial's 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich's Ataxia and First Quarter 2023 Financial Results
BALA CYNWYD, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea...